ArticleMolecular therapy. Methods & clinical development2016
Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9.
Article in Molecular therapy. Methods & clinical development, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- Systemic dual-gene therapy reverses biochemical intoxication in the central metabolic compartment of Bckdha-/- mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Tumor-associated macrophage-related strategies for glioma immunotherapy.NPJ precision oncology · 2023Review
- Efficient Delivery ofGenes · 2023Article
- Syndecan-4 Mediates the Cellular Entry of Adeno-Associated Virus 9.International journal of molecular sciences · 2023Article
- Chemogenetic manipulation of astrocyte activity at the synapse- a gateway to manage brain disease.Frontiers in cell and developmental biology · 2023Review
- Neuronal circuitry for recognition memory of object and place in rodent models.Neuroscience and biobehavioral reviews · 2022Review
- Strategies for Targeting Neural Circuits: How to Manipulate Neurons Using Virus Vehicles.Frontiers in neural circuits · 2022Review
- Brain Interleukin-17A contributes to neuroinflammation and cardiac dysfunction in rats with myocardial infarction.Frontiers in neuroscience · 2022Article
- Protein LY6E as a candidate for mediating transport of adeno-associated virus across the human blood-brain barrier.Journal of neurovirology · 2020Article
- rAAV-Mediated Cochlear Gene Therapy: Prospects and Challenges for Clinical Application.Journal of clinical medicine · 2020Review
- Genetic targeting of astrocytes to combat neurodegenerative disease.Neural regeneration research · 2020Article
- Cardiac Fibrosis and Cardiac Fibroblast Lineage-Tracing: Recent Advances.Frontiers in physiology · 2020Review
- Altered DNA methylation of TRIM13 in diabetic nephropathy suppresses mesangial collagen synthesis by promoting ubiquitination of CHOP.EBioMedicine · 2020Article
- Selection of an Efficient AAV Vector for Robust CNS Transgene Expression.Molecular therapy. Methods & clinical development · 2019Article
- Real-Time Monitoring of Exosome Enveloped-AAV Spreading by Endomicroscopy Approach: A New Tool for Gene Delivery in the Brain.Molecular therapy. Methods & clinical development · 2019Article
- Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans.Nature neuroscience · 2019Article
- Intravascular injections of adenoassociated viral vector serotypes rh10 and PHP.B transduce murine sciatic nerve axons.Neuroscience letters · 2019Article
- Cell-specific CRISPR-Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins.Nucleic acids research · 2019Article
- Live-Animal Epigenome Editing: Convergence of Novel Techniques.Trends in genetics : TIG · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
The capacity of certain adeno-associated virus (AAV) vectors to cross the blood-brain barrier after intravenous delivery offers a unique opportunity for noninvasive brain delivery. However, without a well-tailored system, the use of a peripheral route injection may lead to undesirable transgene expression in nontarget cells or organs. To refine this approach, the present study characterizes the transduction profiles of new self-complementary AAV9 (scAAV9) expressing the green fluorescent protein (GFP) either under an astrocyte (glial fibrillary acidic (GFA) protein) or neuronal (Synapsin (Syn)) promoter, after intravenous injection of adult mice (2 × 10
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.